The DOI matches its Crossref record.
Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma
Open accessAbstract
Purpose: To improve the clinical management of human hepatocellular carcinoma (HCC) by accurate identification, at diagnosis, of patients at risk of recurrence after primary treatment for HCC. Experimental Design: Two clinicopathologic variables available at diagnosis, vascular invasion and cirrhosis, together with molecular profiling using Affymetrix human HG-U133A and HG-U133B oligonucleotide probe arrays, were used to identify recurrent HCC disease. Results: HCC patients presented clinically at diagnosis with vascular invasion and cirrhosis showed a high rate (78-83%) of developing recurrent disease within 6 to 35 months. In comparison, most of the HCC patients (80-100%) without vascular invasion and cirrhosis remained disease-free. However, the risk of recurrent disease for HCC patients with either vascular invasion or cirrhosis could not be accurately ascertained. Using a pool of 23 HCC patients with either vascular invasion or cirrhosis as training set, a 57-gene signature was derived and could predict recurrent disease at diagnosis, with 84% (sensitivity 86%, specificity 82%) accuracy, for a totally independent test set of 25 HCC patients with either vascular invasion or cirrhosis. On further analysis, the disease-free rate was significantly different between patients that were predicted to recur or not to recur in the test group (P = 0.002). Conclusion: We have presented data to show that by incorporating the status of vascular invasion and cirrhosis available at diagnosis for patients with HCC after partial curative hepatectomy and a novel 57-member gene signature, we could accurately stratify HCC patients with different risks of recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rodríguez-Perálvarez, M., Luong, T. V., Andreana, L., Meyer, T., Dhillon, A. P., & Burroughs, A. K. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2513-1 · Cited by 657
Molecular mechanisms of hepatocellular carcinoma
Aravalli, R. N., Steer, C. J., & Cressman, E. N. K. (2008) · Hepatology · doi:10.1002/hep.22580 · Cited by 625
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
MicroRNA involvement in hepatocellular carcinoma
Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00533.x · Cited by 304
Identification of Circulating MicroRNA Signatures for Breast Cancer Detection
Chan, M., Liaw, C. S., Ji, S. M., Tan, H. H., Wong, C. Y., Thike, A. A., Tan, P. H., Ho, G. H., & Lee, A. S.-G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3401 · Cited by 274
Metadata
- Authors
- Wang, S. M., Ooi, L. L. P. J., & Hui, K. M.
- Venue
- Clinical Cancer Research
- Published
- 2007-11-01
- Volume
- 13
- Issue
- 21
- Pages
- 6275-6283
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2123673510
- Cited by
- 198
- References
- 0
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-2236
- The paper
- Wang, S. M., Ooi, L. L. P. J., & Hui, K. M. (2007). Identification and Validation of a Novel Gene Signature Associated with the Recurrence of Human Hepatocellular Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-2236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.